AI Stock Analysis - AIM ImmunoTech (AIM)
Analysis generated June 1, 2026.
AIM ImmunoTech Inc. is a biopharmaceutical company that focuses on the research and development of pharmaceutical therapeutics to treat immune system disorders, infectious diseases, and certain cancers. AIM's primary product is Ampligen, also known as rintatolimod, which has been involved in several clinical trials for various indications, including Chronic Fatigue Syndrome (CFS) and certain cancers. The company is headquartered in Florida, USA.
Stock Alerts - AIM ImmunoTech (AIM)
 |
AIM ImmunoTech | June 15 Price is up by 6.7% in the last 24h. |
|
AIM ImmunoTech | June 12 Price is down by -10.9% in the last 24h. |
|
AIM ImmunoTech | June 10 Price is up by 6.2% in the last 24h. |
|
AIM ImmunoTech | June 9 Price is down by -9.3% in the last 24h. |
Download our app on iOS or Android to get future alerts delivered in real-time.
Alternative Data for AIM ImmunoTech
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 76 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 100 | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 86 | Sign up | Sign up | Sign up |
| Reddit Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 346 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 34,832 | Sign up | Sign up | Sign up |
| X Followers | 3,463 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 34 | Sign up | Sign up | Sign up |
About AIM ImmunoTech
AIM ImmunoTech Inc., an immunpharmaceutical company, focuses on research and development of therapies to treat multiple types of cancers, viruses, and immunodeficiency disorders in the United States. The company is headquartered in Ocala, Florida.
| Price | $0.39 |
| Target Price | Sign up |
| Volume | 41,120 |
| Market Cap | $11M |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American RulesJune 9 - GlobeNewswire |
|
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerJune 8 - GlobeNewswire |
|
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency DeclarationMay 27 - GlobeNewswire |
|
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private PlacementMay 20 - GlobeNewswire |
|
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical PrioritiesMay 19 - GlobeNewswire |
|
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic CancerMay 14 - GlobeNewswire |
Insider Transactions View All
| Rodino Peter W III filed to buy 401,762 shares at $0.1. April 4 '25 |
| Equels Thomas K filed to buy 1,899,029 shares at $0.1. April 7 '25 |
| Equels Thomas K filed to buy 1,858,029 shares at $0.1. March 6 '25 |
| Equels Thomas K filed to buy 1,764,029 shares at $0.1. March 4 '25 |
| Equels Thomas K filed to buy 1,808,029 shares at $0.1. March 5 '25 |
Similar companies
Read more about AIM ImmunoTech (AIM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, business outlook & linkedin employees.
FAQ - AIM ImmunoTech
The Market Cap of AIM ImmunoTech is $11M.
Currently, the price of one share of AIM ImmunoTech stock is $0.39.
The AIM stock price chart above provides a comprehensive visual representation of AIM ImmunoTech's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling AIM ImmunoTech shares. Our platform offers an up-to-date AIM stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, AIM ImmunoTech (AIM) does not offer dividends to its shareholders. Investors interested in AIM ImmunoTech should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of AIM ImmunoTech are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
